Paper22913596
Toxicological and pharmacokinetic properties of chemically modified siRNAs targeting p53 RNA following intravenous administration.
Thompson JD and 7 others. Nucleic Acid Ther, 2012. Cited by 69 papers, by iCite.
Cite this record
ConductScience Library. Toxicological and pharmacokinetic properties of chemically modified siRNAs targeting p53 RNA following intravenous administration. Papers, record 22913596. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/22913596
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Toxicological and pharmacokinetic properties of chemically modified siRNAs targeting p53 RNA following intravenous administration.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| RNA, Messenger | Major topic |
| RNA, Small Interfering | Major topic |
| Tumor Suppressor Protein p53 | Major topic |
| Administration, Intravenous | |
| Animals | |
| Area Under Curve | |
| Drug Evaluation, Preclinical | |
| Female | |
| Kidney | |
| Macaca fascicularis | |
| Male | |
| Metabolic Clearance Rate | |
| Rats | |
| Rats, Sprague-Dawley | |
| Renal Insufficiency | |
| Tissue Distribution |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| P30 DK079312 | NIDDK NIH HHS | United States | P30DK079312 | PubMed and NIH |
Source NIH RePORTER
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT02530359 | Pirfenidone Effect on the Recovery of Renal Function in Septic Acute Kidney Injury | Background |
Source ClinicalTrials.gov
References16
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 10640282 | Chemically modified oligonucleotides exhibit decreased immune stimulation in mice. | J Pharmacol Exp Ther | 2000 | https://conductscience.org/library/papers/10640282 | PubMed |
| 2 | 12771196 | Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. | Nucleic Acids Res | 2003 | https://conductscience.org/library/papers/12771196 | PubMed |
| 3 | 9236854 | Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. | Anticancer Drug Des | 1997 | https://conductscience.org/library/papers/9236854 | PubMed |
| 4 | 16714375 | Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. | Drug Metab Dispos | 2006 | https://conductscience.org/library/papers/16714375 | PubMed |
| 5 | 15665597 | Distribution and excretion of a phosphorothioate oligonucleotide in rats with experimentally induced renal injury. | Oligonucleotides | 2004 | https://conductscience.org/library/papers/15665597 | PubMed |
| 6 | 9310342 | Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration. | Biochem Pharmacol | 1997 | https://conductscience.org/library/papers/9310342 | PubMed |
| 7 | 9351904 | Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression. | Drug Metab Dispos | 1997 | https://conductscience.org/library/papers/9351904 | PubMed |
| 8 | 19470675 | siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. | J Am Soc Nephrol | 2009 | https://conductscience.org/library/papers/19470675 | PubMed |
| 9 | 4893532 | Methylated ribonucleic acids. | Physiol Rev | 1969 | https://conductscience.org/library/papers/4893532 | PubMed |
| 10 | 10960462 | Pharmacokinetics and tissue distribution of a ribozyme directed against hepatitis C virus RNA following subcutaneous or intravenous administration in mice. | Hepatology | 2000 | https://conductscience.org/library/papers/10960462 | PubMed |
| 11 | 10367666 | Synthetic oligonucleotides: the development of antisense therapeutics. | Toxicol Pathol | 1999 | https://conductscience.org/library/papers/10367666 | PubMed |
| 12 | 11471755 | Ribozyme pharmacokinetic screening for predicting pharmacodynamic dosing regimens. | Curr Issues Mol Biol | 2000 | https://conductscience.org/library/papers/11471755 | PubMed |
| 13 | 10435752 | Pharmacokinetics of an antiangiogenic ribozyme (ANGIOZYME) in the mouse. | Antisense Nucleic Acid Drug Dev | 1999 | https://conductscience.org/library/papers/10435752 | PubMed |
| 14 | 9573607 | Antisense therapeutics. | Biotechnol Genet Eng Rev | 1998 | https://conductscience.org/library/papers/9573607 | PubMed |
| 15 | 7929417 | Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. | J Biol Chem | 1994 | https://conductscience.org/library/papers/7929417 | PubMed |
| 16 | 18480187 | Complement cascade activation after an acute psychological stress task. | Psychosom Med | 2008 | https://conductscience.org/library/papers/18480187 | PubMed |
Cited by35
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 69 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41282595 | siRNA-mediated therapeutic approaches improve acute kidney injury and limit its worsening. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/41282595 | PubMed |
| 37892179 | Enabling mRNA Therapeutics: Current Landscape and Challenges in Manufacturing. | Biomolecules | 2023 | https://conductscience.org/library/papers/37892179 | PubMed |
| 37868774 | Using RNA-based therapies to target the kidney in cardiovascular disease. | Front Cardiovasc Med | 2023 | https://conductscience.org/library/papers/37868774 | PubMed |
| 37430086 | Where should siRNAs go: applicable organs for siRNA drugs. | Exp Mol Med | 2023 | https://conductscience.org/library/papers/37430086 | PubMed |
| 36960337 | Still finding ways to augment the existing management of acute and chronic kidney diseases with targeted gene and cell therapies: Opportunities and hurdles. | Front Med (Lausanne) | 2023 | https://conductscience.org/library/papers/36960337 | PubMed |
| 35680378 | RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies. | J Pharmacol Exp Ther | 2023 | https://conductscience.org/library/papers/35680378 | PubMed |
| 35055900 | RNAi for Western Corn Rootworm Management: Lessons Learned, Challenges, and Future Directions. | Insects | 2022 | https://conductscience.org/library/papers/35055900 | PubMed |
| 34638486 | Nucleic Acid Drugs-Current Status, Issues, and Expectations for Exosomes. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34638486 | PubMed |
| 34567044 | RNA Interference-Based Forest Protection Products (FPPs) Against Wood-Boring Coleopterans: Hope or Hype? | Front Plant Sci | 2021 | https://conductscience.org/library/papers/34567044 | PubMed |
| 34277620 | The Genomic Response to TGF-β1 Dictates Failed Repair and Progression of Fibrotic Disease in the Obstructed Kidney. | Front Cell Dev Biol | 2021 | https://conductscience.org/library/papers/34277620 | PubMed |
| 33997814 | Transient siRNA-mediated protein knockdown in mouse followed by feeding/starving cycle and liver tissue analysis. | STAR Protoc | 2021 | https://conductscience.org/library/papers/33997814 | PubMed |
| 33513339 | The growth of siRNA-based therapeutics: Updated clinical studies. | Biochem Pharmacol | 2021 | https://conductscience.org/library/papers/33513339 | PubMed |
| 33376785 | Kidney-Targeted Cytosolic Delivery of siRNA Using a Small-Sized Mirror DNA Tetrahedron for Enhanced Potency. | ACS Cent Sci | 2020 | https://conductscience.org/library/papers/33376785 | PubMed |
| 33043785 | Large animal models for translational research in acute kidney injury. | Ren Fail | 2020 | https://conductscience.org/library/papers/33043785 | PubMed |
| 32893005 | Paving the Road for RNA Therapeutics. | Trends Pharmacol Sci | 2020 | https://conductscience.org/library/papers/32893005 | PubMed |
| 32709999 | Dendrimer-coated carbon nanotubes deliver dsRNA and increase the efficacy of gene knockdown in the red flour beetle Tribolium castaneum. | Sci Rep | 2020 | https://conductscience.org/library/papers/32709999 | PubMed |
| 32670333 | Biosafety of GM Crop Plants Expressing dsRNA: Data Requirements and EU Regulatory Considerations. | Front Plant Sci | 2020 | https://conductscience.org/library/papers/32670333 | PubMed |
| 32561705 | Therapeutic siRNA: state of the art. | Signal Transduct Target Ther | 2020 | https://conductscience.org/library/papers/32561705 | PubMed |
| 32391029 | Safety Considerations for Humans and Other Vertebrates Regarding Agricultural Uses of Externally Applied RNA Molecules. | Front Plant Sci | 2020 | https://conductscience.org/library/papers/32391029 | PubMed |
| 32311310 | Pharmacodynamic and Pharmacokinetic Properties of Full Phosphorothioate Small Interfering RNAs for Gene Silencing In Vivo. | Nucleic Acid Ther | 2021 | https://conductscience.org/library/papers/32311310 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/22913596
GET https://conductscience.org/api/papers/v1/22913596/cited_by?page=2